446 related articles for article (PubMed ID: 12800187)
1. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
[TBL] [Abstract][Full Text] [Related]
2. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
[TBL] [Abstract][Full Text] [Related]
3. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
Uccini S; Mannarino O; McDowell HP; Pauser U; Vitali R; Natali PG; Altavista P; Andreano T; Coco S; Boldrini R; Bosco S; Clerico A; Cozzi D; Donfrancesco A; Inserra A; Kokai G; Losty PD; Nicotra MR; Raschellà G; Tonini GP; Dominici C
Clin Cancer Res; 2005 Jan; 11(1):380-9. PubMed ID: 15671569
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
6. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
7. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
8. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
10. Stem cell factor suppresses apoptosis in neuroblastoma cell lines.
Timeus F; Crescenzio N; Valle P; Pistamiglio P; Piglione M; Garelli E; Ricotti E; Rocchi P; Strippoli P; Cordero di Montezemolo L; Madon E; Ramenghi U; Basso G
Exp Hematol; 1997 Nov; 25(12):1253-60. PubMed ID: 9357969
[TBL] [Abstract][Full Text] [Related]
11. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
13. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway.
Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
Dig Dis Sci; 2007 Sep; 52(9):2292-300. PubMed ID: 17410437
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
15. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
16. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors.
Beck D; Gross N; Brognara CB; Perruisseau G
Blood; 1995 Oct; 86(8):3132-8. PubMed ID: 7579408
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C-δ-mediated recycling of active KIT in colon cancer.
Park M; Kim WK; Song M; Park M; Kim H; Nam HJ; Baek SH; Kim H
Clin Cancer Res; 2013 Sep; 19(18):4961-71. PubMed ID: 23881925
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
20. KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes.
Bellone G; Smirne C; Carbone A; Buffolino A; Scirelli T; Prati A; Solerio D; Pirisi M; Valente G; Nano M; Emanuelli G
Int J Oncol; 2006 Oct; 29(4):851-9. PubMed ID: 16964380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]